Product Description
Oritavancin is a lipoglycopeptide with bactericidal activity against gram-positive bacteria. (Sourced from: https://www.nejm.org/doi/full/10.1056/nejmoa1310422)
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Jordan | Latvia | Lithuania | Poland | Portugal | Saudi Arabia | Slovakia | Spain | Sweden | Switzerland | United Kingdom | United States
Approved Indications: Gram-Positive Bacterial Infections | Gram-Positive Bacterial Infections
Known Adverse Events: Headache | Pruritus | Abscess | Chills | Diarrhea
Company: Melinta
Company Location: MORRISTOWN NJ 07963
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, Greece, Latvia, Lithuania, Poland, Portugal, Romania, Spain, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Skin Diseases, Bacterial
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2022-001297-63 | P2 |
Active, not recruiting |
Unknown |
2026-04-05 |
|
ML-ORI-201 | P2 |
Recruiting |
Skin Diseases, Bacterial |
2025-06-15 |